Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI is the most innovative MedTech Company in Scandinavia in 2023
We at PHI are humbled that the Global Health & Pharma Magazine has awarded us as the most innovative MedTech Company in Scandinavia in 2023!
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on 9 May 2023. The following resolutions were passed at the meeting:
TO 3 Warrants Subscribed to 100 %
On 2 May 2023, the exercise period for warrants of series TO 3, which were issued in connection with PHI AB’s rights issue of units that were announced on 22 February 2022, ended. […] The proceeds of the TO 3 warrants amount to approximately SEK 12.7 million before the deduction of transaction-related costs, corresponding to a subscription rate of 100 percent.
Cytocentric measurement for regenerative medicine
PHI, together with our alliance for advancing cell-based biomanufacturing with Wake Forest Institute for Regenerative Medicine, BioSpherix, global analytics company SAS and others, has recently published a paper in Frontiers in Medical Technology about the critical cell and process parameters for cell and tissue products as well as technologies available in Regenerative Medicine. Here we highlighted more about the “what, why and how” of cyctocentric measurement.
BioStock: PHI on how TO 3 proceeds will be used
BioStock talked to CEO Patrik Eschricht to learn how the TO 3 proceeds would be used.
Last day of trading in warrants of series TO 3 is 27 April 2023
Thursday, 27 April 2023, is the last day of trading in warrants of series TO 3, which were issued in connection with PHI’s rights issue of units that was announced on 22 February 2022. The exercise period runs until and including 2 May 2023.
Insider Acquisitions in Phase Holographic Imaging
CEO Patrik Eschricht, chairman Peter Egelberg and deputy board member Ann Christine Egelberg has recently acquired additional holdings in Phase Holographic Imaging.
PHI enters into underwriting commitment with Altium in ongoing exercise of TO 3 warrants
PHI announces that the Company’s largest shareholder Altium and PHI has agreed on an underwriting commitment free-of-charge in the ongoing exercise of warrants of series TO 3.
Altium S.A. exercised all their obtained warrants TO 3
PHI announces that Altium S.A. exercised all their obtained warrants TO 3.
The exercise period for warrants of series TO 3 begins today
PHI announces that the exercise period for warrants of series TO 3 begins today.